SAMe, a naturally occurring molecule synthesized by the “one-carbon cycle” which is dependent on B12 and folate, is a precursor to creatine, phosphatidylcholine, coQ10, carnitine, and myelin in addition to participating in production of neurotransmitters has been approved as a nutraceutical since the 1990s and prescribed in Europe for depression for 3 decades.
With numerous double-blind, and comparator trials, it has proven efficacy for depression. While I do not subscribe to one-pill cures, whether pharmacologic or natural, I do find it compelling that this data does exist and yet, agents that support endogenous bodily processes are considered “alternative” or “complementary”.
In the latest study, subjects were randomized to SAMe(1600–3200mg/daily), escitalopram(10–20 mg/daily) or placebo for 12 weeks of double blind treatment. The authors report:
“Our results suggest that SAMe (S-Adenosylmethionine)is significantly more effective than placebo in reducing depressed mood,while the SSRI comparator did not achieve this result.”
Specifically,
“Response rates at endpoint were 45%, 31%, and 26% for SAMe, escitalopram, and placebo,respectively;while remission rates(HAM-Dr7) were 34% for SAMe,23% for escitalopram, and 6% for placebo.
Resolving depression from its root is my mission for those who struggle with this reversible condition, however, data like this supports the use of a safe agent that the body is primed to recognize, as being effective, at least in a subset of patients who benefit from methylation support.
By Dr Kelly Brogan